Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

Amgen’s focus on blood cell medications continued in the 2000s, with the approval of Aranesp for the treatment of anaemic patients with chronic renal failure, and the 2002 approval of Neulasta ...

Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...

Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Amgen in a research note issued on Wednesday, March 5th. William Blair analyst M. Phipps anticipates that the ...

Aranesp, Neulasta, and Repatha, among others. On March 4, David Amsellem, analyst at Piper Sandler, reiterated a Buy rating on the stock, with a price target of $329. Amgen Inc. (NASDAQ ...

Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...